• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Prenetics' IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications Services

    12/5/24 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email
    • Mission Launched via SpaceX CRS-31; Experiment Now Underway on the ISS
    • Collaboration Aims to Enhance Healthspan on Earth and Improve Astronaut Health in Space
    • IM8, a new premium supplements brand launched officially on November 18th on IM8health.com

    CHARLOTTE, N.C., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Prenetics' IM8 is excited to announce that its groundbreaking month-long space experiment, in partnership with the University of Oxford and supported by Space Applications Services and Metavisionaries, is now underway aboard the International Space Station (ISS). Launched via SpaceX CRS-31 on November 4th at 9:29 pm EST, the mission aims to study accelerated aging and longevity by leveraging microgravity's unique environment to accelerate aging processes at the cellular level.

    Dr. Jim Green, former Chief Scientist of NASA and a key member of IM8's Scientific Advisory Board said, "Space exploration has a remarkable history of leading to significant medical breakthroughs that benefit humanity. For example, research on bone density loss in astronauts has advanced our understanding and treatment of osteoporosis on Earth. Additionally, microgravity has facilitated the growth of high-quality protein crystals, aiding in the development of more effective drugs for conditions such as cancer and diabetes. By investigating accelerated aging in space, we have the potential to uncover new insights into cellular processes that could lead to groundbreaking interventions for age-related diseases."

    Microgravity Provides Accelerated Aging Model for Groundbreaking Autophagy Research

    Microgravity offers a unique opportunity to study aging processes more rapidly than on Earth. The absence of Earth's gravity affects human physiology in ways that mimic the aging process, including cell degeneration, oxidative stress, and DNA damage. This mission utilizes this phenomenon to investigate the cellular mechanisms behind aging and explore potential interventions.

    The experiment focuses on autophagy, the process by which cells remove and recycle damaged components. Autophagy declines with age, contributing to cellular aging and associated health issues such as decreased immune function and chronic inflammation. By enhancing autophagy, it may be possible to mitigate these effects and improve overall healthspan.

    Aims to Enhance Healthspan on Earth and Improve Astronaut Health in Space

    The mission involves sending specially designed 3D organoids—miniature, simplified versions of human tissues—into space.

    Dr. Ghada Alsaleh, Director of the Space Innovation Lab at the University of Oxford, highlighted the study's significance: "Microgravity might provide an accelerated aging model, allowing us to study cellular processes within a compressed timeframe. Our research aims to understand aging pathways in space to help us better moderate and manage aging processes on Earth, as well as explore whether enhancing autophagy can mitigate cellular aging. This work could have profound implications for improving healthspan on Earth and protecting astronaut health during space missions."

    This mission utilizes a specially designed science cube to house the CRT8 ingredients for a full month aboard the ISS. The cube is accommodated inside the ICE Cubes Facility once onboard; this platform provides power and data to the payload, as well as real-time connectivity with ground control. This setup enables researchers back in Oxford to monitor and interact with the experiment in real-time.

    "Our collaboration with the University of Oxford represents an important milestone in our commitment to advancing health science," said Danny Yeung, CEO of Prenetics / IM8. "By studying accelerated aging in microgravity, we aim to unlock new insights into cellular health that could enhance healthspan on Earth and improve astronaut health in space."

    The findings from this pioneering study are expected to benefit IM8's future endeavors:

    • Enhanced Product Efficacy: Understanding how CRT8 ingredients influence autophagy in an accelerated aging model allows us to optimize our supplements for maximum effectiveness in supporting healthspan and longevity.
    • Innovation and New Product Development: Discoveries from the study may lead to the creation of new supplements targeting specific aging pathways, reinforcing IM8's position at the forefront of wellness innovation.

    IM8 Launched Officially on November 18th on IM8health.com

    As part of its commitment to advancing health and longevity, IM8 unveiled its line of premium, science-backed supplement solutions on November 18th at IM8health.com. Now shipping to 31 countries and regions, IM8 introduces two groundbreaking products—Daily Ultimate Essentials and Daily Ultimate Longevity—designed to support optimal daily nutrition and promote healthy aging, backed by clinical trials and third-party testing.

    ABOUT PRENETICS

    Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand and Europa, the largest sports distribution company in the USA. Our clinical division is led by Insighta, our $200 million venture focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for comprehensive genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer comprehensive DNA tests. Each of Prenetics' units synergistically enhances our global impact on health, embodying our commitment to ‘enhancing life through science'. To learn more about Prenetics, please visit prenetics.com.

    ABOUT SPACE APPLICATIONS SERVICES

    Space Applications Services (SpaceApps) is an independent Belgian company founded in 1987, with offices in Europe (Belgium and the Netherlands) and a subsidiary, Aerospace Applications North America, in Houston, Texas (USA). With a strong focus on R&D, the company collaborates with global partners to develop innovative products, systems and solutions, while providing services to the aerospace and security markets and related industries. The company's expertise spans various segments, including robotics and AI, flight and ground systems, crewed and autonomous spacecraft, mission control centres and information systems, payload integration and operations.

    Through the ICE Cubes Service, SpaceApps provides fast, direct and affordable access to space for research, technology and education, on a commercial basis. The end-to-end service facilitates a frequent and regular ‘launch-and-return' capability to/from the International Space Station, and offers a unique real-time interaction capability. To date, over 30 payloads, devices and experiments have been successfully flown to the ISS, and operated on board the station. Key markets include health and life sciences, materials, agrifood, and technology.

    ABOUT METAVISIONARIES

    Metavisionaries is a space and frontier technology company that is dedicated to advancing education, empowering the next generation of pioneers, and making space research and technology accessible to all. Founded by visionary leaders and former NASA scientists, Metavisionaries is dedicated to democratizing access to space research and fostering global innovation. Through our joint venture with Space Application Services, Metaspace, we provide direct access to frontier technologies and the International Space Station to industry, academia and the wider community.

    Our goal is not only to inspire and educate, but to equip students, professionals and organisations with practical skills and knowledge that can be directly applied to their future careers and industries. 

    Investor Relations Contact:

    Shannon Devine

    MZ North America

    [email protected]

    (203) 741-8811

    Angela Cheung

    Investor Relations / Corporate Finance

    Prenetics Global Limited

    [email protected]



    Primary Logo

    Get the next $PRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What is the primary focus of the mission launched via SpaceX CRS-31?

      The mission, launched via SpaceX CRS-31, focuses on studying accelerated aging and longevity using microgravity to examine cellular aging processes more rapidly than on Earth.

    • Who are the key collaborators involved in this space experiment?

      The collaboration involves Prenetics' IM8, the University of Oxford, Space Applications Services, and Metavisionaries, aiming to improve healthspan on Earth and enhance astronaut health in space.

    • What cellular process is the focus of the research being conducted aboard the ISS?

      By leveraging microgravity, the study investigates autophagy, the cellular mechanism that declines with age, to help identify interventions for age-related diseases.

    • What is the launch date and the focus of the IM8 premium supplements line?

      IM8 was officially launched on November 18th and offers two products: Daily Ultimate Essentials and Daily Ultimate Longevity, aimed at promoting health and wellness.

    • What potential benefits could arise from the findings of this study for IM8's product offerings?

      The findings from this mission could lead to optimized supplements that enhance healthspan and longevity and inform new product development targeting specific aging pathways.

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    2/11/2026$36.00Buy
    Roth Capital
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Prenetics Group Ltd. with a new price target

    Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00

    2/11/26 7:52:37 AM ET
    $PRE
    Blank Checks
    Finance

    Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

    Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

    1/18/23 7:56:45 AM ET
    $PRE
    Blank Checks
    Finance

    Citigroup initiated coverage on Prenetics Group Ltd.

    Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

    7/12/22 11:48:35 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    SEC Filings

    View All

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    2/18/26 9:28:49 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    2/17/26 4:33:52 PM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 6-K filed by Prenetics Global Limited

    6-K - Prenetics Global Ltd (0001876431) (Filer)

    2/17/26 8:29:14 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY

    Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium he

    2/18/26 9:11:26 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity

    Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced Pre-Market on February 18, 2026 NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the completion of the sale of its 35% equity interest in Insighta to Tencent for total cash consideration of $70 million. The transaction provides a substantial and immediate increase in Prenetics' cash resources, further strengthening the Company's financial posi

    2/17/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Leadership Updates

    Live Leadership Updates

    View All

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board

    -  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation -  Following strategic divestiture, Prenetics leverages strengthened $117M balance sheet to execute comprehensive Bitcoin strategy with board-approved majority allocation, institutional financing partnerships, and alpha-generating initiatives. CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading health sciences company, today announced it has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million Bitcoin purchase of 187.42 BTC at an averag

    6/18/25 8:45:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

    LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

    7/1/24 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance

    $PRE
    Financials

    Live finance-specific insights

    View All

    Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY

    Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium he

    2/18/26 9:11:26 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Wednesday, February 18, 2026Time:10:00 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878

    2/11/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History

    Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial

    11/10/25 7:24:27 AM ET
    $EXOD
    $PRE
    Finance: Consumer Services
    Finance
    Blank Checks

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/14/24 12:30:15 PM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    2/5/24 6:05:14 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

    SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

    11/27/23 6:05:43 AM ET
    $PRE
    Blank Checks
    Finance